Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Schizophrenia Bulletin
Hiroyuki UchidaDavid Mamo

Abstract

It remains unknown as to whether the antipsychotic dose needed for the acute-phase treatment of schizophrenia is also necessary for relapse prevention. To compare the efficacy between standard dose [(World Health Organization daily defined dose (DDD)] vs low dose (≥50% to <1 DDD) or very low dose (<50% DDD) for relapse prevention in schizophrenia. Double-blind, randomized, controlled trials with a follow-up duration of ≥24 weeks, including ≥2 dosage groups of the same antipsychotic drug for relapse prevention in schizophrenia, were searched using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE (last search: August 2009). Data on overall treatment failure, hospitalization, relapse, and dropouts due to side effects were extracted and combined in a meta-analysis. Thirteen studies with 1395 subjects were included in this meta-analysis. Compared with the standard-dose treatment, the low-dose therapy did not show any statistically significant difference in overall treatment failure or hospitalization, while the standard dose showed a trend-level (P = .05) superiority in risk of relapse. The very low-dose group was inferior to the standard-dose group in all efficacy parameters. No significant difference was fou...Continue Reading

References

Jun 1, 1987·Archives of General Psychiatry·S R MarderP R May
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Aug 1, 1983·Archives of General Psychiatry·J M KaneJ Ramos-Lorenzi
Sep 1, 1995·Archives of General Psychiatry·D V JesteL A McAdams
Dec 1, 1994·The American Journal of Psychiatry·L B InderbitzinC Waternaux
Jan 1, 1996·Psychiatric Services : a Journal of the American Psychiatric Association·M O HuttunenM Romanov
Dec 24, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·M A DellvaC M Beasley
Sep 29, 2001·Journal of Clinical Epidemiology·J A Sterne, M Egger
Dec 12, 2001·Schizophrenia Research·Dawn I VelliganAlexander L Miller
Apr 2, 2002·The American Journal of Psychiatry·John M KaneRobert Conley
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Aug 5, 2004·The Journal of Clinical Psychiatry·Alex HoferW Wolfgang Fleischhacker
Sep 16, 2004·The Journal of Clinical Psychiatry·Maria A RettenbacherWolfgang W Fleischhacker
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Mar 4, 2006·The American Journal of Psychiatry·Henrik Berg RasmussenThomas Werge
Mar 9, 2006·JAMA : the Journal of the American Medical Association·Gilda PiaggioUNKNOWN CONSORT Group
Jan 16, 2009·The New England Journal of Medicine·Wayne A RayC Michael Stein
Feb 5, 2009·The Journal of Clinical Psychiatry·Hiroyuki UchidaShitij Kapur
Feb 20, 2009·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Hiroyuki UchidaDavid C Mamo
May 15, 2009·The New England Journal of Medicine·Ross J Baldessarini
Jan 1, 1996·European Psychiatry : the Journal of the Association of European Psychiatrists·C BarbuiS Garattini
Sep 19, 2009·Clinical Pharmacology and Therapeutics·H UchidaD C Mamo

❮ Previous
Next ❯

Citations

Jun 4, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Takashi TsuboiHiroyuki Uchida
Jan 11, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yuya MizunoHiroyuki Uchida
Jul 13, 2013·Schizophrenia Research·Maxine X PatelThomas R E Barnes
Jun 22, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang Fleischhacker, Hiroyuki Uchida
Aug 28, 2016·Psychiatry Research·Vijay KumarBangalore N Gangadhar
Jul 28, 2016·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Aug 5, 2015·Therapeutic Advances in Psychopharmacology·Peter HjorthPovl Munk-Jørgensen
Oct 10, 2018·Journal of Clinical Psychopharmacology·Hideaki TaniHiroyuki Uchida
Jun 13, 2019·Journal of Clinical Psychopharmacology·Chisa OzawaHiroyuki Uchida
Jul 25, 2014·Human Psychopharmacology·Takefumi SuzukiMasaru Mimura
Nov 27, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideaki TaniHiroyoshi Takeuchi
Dec 17, 2019·The American Journal of Psychiatry·Stefan LeuchtJohn M Davis
May 2, 2020·Psychiatric Services : a Journal of the American Psychiatric Association·Daniel Guinart, John M Kane
Aug 1, 2013·Journal of Clinical Psychopharmacology·Sho MoriguchiHiroyuki Uchida
Jun 2, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Christoph U CorrellJohn M Kane
Apr 8, 2020·Neuropsychiatric Disease and Treatment·Nobuhiro NagaiHiroyuki Uchida
Jun 2, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·W Wolfgang Fleischhacker
Sep 1, 2020·Deutsches Ärzteblatt International·Alkomiet HasanWolfgang Gaebel
Jan 31, 2021·Behavioural Brain Research·Daria A ChestnykhChristian P Müller
Jul 24, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Chi-Un PaePrakash S Masand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The American Journal of Psychiatry
Chuan-Yue WangRisperidone Maintenance Treatment in Schizophrenia (RMTS) investigators
Journal of Clinical Pharmacology
Kristin L BigosRobert R Bies
© 2022 Meta ULC. All rights reserved